Lantern Pharma (NASDAQ: LTRN)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-10-31 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.410 | 0.1100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lantern Pharma (NASDAQ: LTRN) through any online brokerage.
Other companies in Lantern Pharma’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Lumos Pharma (NASDAQ:LUMO), Evaxion Biotech (NASDAQ:EVAX), Aligos Therapeutics (NASDAQ:ALGS) and Sensei Biotherapeutics (NASDAQ:SNSE).
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by HC Wainwright & Co. on Friday, March 11, 2022. The analyst firm set a price target for 36.00 expecting LTRN to rise to within 12 months (a possible 483.47% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Lantern Pharma (NASDAQ: LTRN) is $6.17 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Lantern Pharma.
Lantern Pharma’s Q3 earnings are confirmed for Monday, October 31, 2022.
There is no upcoming split for Lantern Pharma.
Lantern Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.